Recently, few studies have shown that imatinib induces tumor regression in patients with unresectable or advanced PVNS. [12] Imatinib is a tyrosine kinase inhibitor which blocks macrophage colony stimulating factor receptors, which is expressed in high levels in most of mononuclear and multinucleated stromal cells and are thought to be responsible for tumor formation. [13] The use of imatinib in this indication is based on the observation of the presence of a t(1;2) translocation in bulk of the tumors, leading to the over expression of active colony-stimulating factor 1, which attracts inflammatory cells that dominate in PVNS. [12,14] No prospective studies on use of imatinib in PVNS are available as of now. [15] Financial support and sponsorship Nil.

No abstract

BACKGROUNDLeukaemia is the most prevalent childhood cancer and Acute Lymphoblastic Leukaemia (ALL) constitutes about 75% of all cases. The most frequent presenting symptoms are fever, weight loss and pallor. Early diagnosis of this haematological malignancy can be helpful for prognosis of disease.